Communiqués Alligator Bioscience AB

Actions

ATORX

SE0000767188

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
1,11 ^SEK	-3,98 %		+2,97 %	+61,10 %

03/06	Alligator Bioscience annonce la publication des résultats positifs de la phase 2 de son principal candidat-médicament, le mitazalimab, dans le traitement de première intention du cancer du pancréas métastatique dans le Lancet Oncology.	CI
23/05	Alligator Bioscience présentera des données positives de phase 2 sur le mitazalimab dans le cancer du pancréas lors de la réunion annuelle de l'ASCO en 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStock: Alligator's mitazalimab data published in The Lancet Oncology	04/06	AQ
Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology	03/06	AQ
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	23/05	AQ
Alligator Bioscience : Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer	21/05	PU
Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer	21/05	AQ
Alligator Bioscience : Announces Publication Highlighting Potential of Next Generation CD40 Agonists in Peer Reviewed Medical Journal "Expert Opinion on Biological Therapy"	20/05	PU
Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal "Expert Opinion on Biological Therapy"	20/05	AQ
Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer	14/05	AQ
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024	07/05	AQ
Alligator Bioscience Q1 2024 - The Next Catalyst Will Be the 18-month Readout	07/05	AQ
Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update	06/05	AQ
BioStock: Orion option exercise triggers milestone payment for Alligator	02/05	AQ
Change in number of shares and votes in Alligator Bioscience AB	30/04	AQ
Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement	26/04	AQ
Last day of trading in paid subscribed units (Sw. BTU) in Alligator	18/04	AQ
Alligator publishes outcome in rights issue	09/04	AQ
Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024	08/04	AQ
Notice of annual general meeting in Alligator Bioscience AB	05/04	AQ
BioStock: Alligator Bioscience on the importance of prolonging life	02/04	AQ
BioStock: Alligator to maximise immuno-oncology innovation	27/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alligator Bioscience AB

Actions

ATORX

SE0000767188

Communiqués

Filtres